February 20, 2008 -- Omnicare Clinical Research, a division of Omnicare (NYSE: OCR) has opened two offices in China, one in Shanghai and the other in Beijing. Omnicare Clinical Research is a CRO specializing in Phase I to Phase IV trials for biopharma and medical device companies. From its new China offices, the company will offer its services in Project Management, Clinical Trial Services, Regulatory Affairs and Business Development. More details...
